CN Patent

CN110461325A — 包括口服或胃部施用依达拉奉的治疗

Assigned to Cuiwei Tw001 Co · Expires 2019-11-15 · 7y expired

What this patent protects

本发明涉及用于医学治疗用途的液体药物组合物，所述液体药物组合物是非络合的3‑甲基‑1‑苯基‑2‑吡唑啉‑5‑酮(依达拉奉)的单相水性溶液，并且包含至少7重量％的水和0.2‑9mg/mL依达拉奉，其中治疗包括口服或胃部施用10‑250mL的液体药物组合物以提供30‑300mg的依达拉奉。

USPTO Abstract

本发明涉及用于医学治疗用途的液体药物组合物，所述液体药物组合物是非络合的3‑甲基‑1‑苯基‑2‑吡唑啉‑5‑酮(依达拉奉)的单相水性溶液，并且包含至少7重量％的水和0.2‑9mg/mL依达拉奉，其中治疗包括口服或胃部施用10‑250mL的液体药物组合物以提供30‑300mg的依达拉奉。

Drugs covered by this patent

Patent Metadata

Patent number
CN110461325A
Jurisdiction
CN
Classification
—
Expires
2019-11-15
Drug substance claim
No
Drug product claim
No
Assignee
Cuiwei Tw001 Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.